Midregional proatrial naturetic peptide (MRproANP) and copeptin (COPAVP) as predictors of all-cause mortality in recently diagnosed mild to moderate COPD-results from COSYCONET
© 2024. The Author(s)..
BACKGROUND: MRproANP and COPAVP are prognostic markers for mortality in chronic obstructive pulmonary disease (COPD). Furthermore, these biomarkers predict mortality due to cardiovascular diseases, which are important prognostically determining comorbidities in patients with COPD. However, less is known about these biomarkers in recently diagnosed mild to moderate COPD. Therefore, we analyzed these biomarkers as potential predictors of mortality in recently diagnosed mild to moderate COPD.
METHODS: The blood biomarkers considered were copeptin (COPAVP), midregional adrenomedullin (MRproADM), midregional proatrial naturetic peptide (MRproANP), and fibrinogen. Analyses were performed in patients with stable "recently diagnosed mild to moderate COPD" defined by GOLD grades 0-2 and diagnosis of COPD ≤ 5 years prior to inclusion into the COSYCONET cohort (COPD and Systemic Consequences-Comorbidities Network), using Cox regression analysis with stepwise adjustment for multiple COPD characteristics, comorbidities, troponin and NT-proBNP.
RESULTS: 655 patients with recently diagnosed mild to moderate COPD were included. In the initial regression model, 43 of 655 patients died during the 6-year follow-up, in the final model 27 of 487. Regression analyses with adjustment for confounders identified COPAVP and MRproANP as statistically robust biomarkers (p < 0.05 each) of all-cause mortality, while MRproADM and fibrinogen were not. The fourth quartile of MRproANP (97 pmol/L) was associated with a hazard ratio of 4.5 (95%CI: 1.6; 12.8), and the fourth quartile of COPAVP (9.2 pmol/L) with 3.0 (1.1; 8.0). The results for MRproANP were confirmed in the total cohort of grade 0-4 (n = 1470 finally).
CONCLUSION: In patients with recently diagnosed mild to moderate COPD, elevated values of COPVP and in particular MRproANP were robust, independent biomarkers for all-cause mortality risk after adjustment for multiple other factors. This suggests that these markers might be considered in the risk assessment of early COPD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Respiratory research - 25(2024), 1 vom: 24. Jan., Seite 56 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fähndrich, S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9001-32-5 |
|---|
| Anmerkungen: |
Date Completed 05.02.2024 Date Revised 05.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12931-024-02690-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367583682 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367583682 | ||
| 003 | DE-627 | ||
| 005 | 20240205232056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12931-024-02690-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1281.xml |
| 035 | |a (DE-627)NLM367583682 | ||
| 035 | |a (NLM)38267944 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fähndrich, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Midregional proatrial naturetic peptide (MRproANP) and copeptin (COPAVP) as predictors of all-cause mortality in recently diagnosed mild to moderate COPD-results from COSYCONET |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.02.2024 | ||
| 500 | |a Date Revised 05.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: MRproANP and COPAVP are prognostic markers for mortality in chronic obstructive pulmonary disease (COPD). Furthermore, these biomarkers predict mortality due to cardiovascular diseases, which are important prognostically determining comorbidities in patients with COPD. However, less is known about these biomarkers in recently diagnosed mild to moderate COPD. Therefore, we analyzed these biomarkers as potential predictors of mortality in recently diagnosed mild to moderate COPD | ||
| 520 | |a METHODS: The blood biomarkers considered were copeptin (COPAVP), midregional adrenomedullin (MRproADM), midregional proatrial naturetic peptide (MRproANP), and fibrinogen. Analyses were performed in patients with stable "recently diagnosed mild to moderate COPD" defined by GOLD grades 0-2 and diagnosis of COPD ≤ 5 years prior to inclusion into the COSYCONET cohort (COPD and Systemic Consequences-Comorbidities Network), using Cox regression analysis with stepwise adjustment for multiple COPD characteristics, comorbidities, troponin and NT-proBNP | ||
| 520 | |a RESULTS: 655 patients with recently diagnosed mild to moderate COPD were included. In the initial regression model, 43 of 655 patients died during the 6-year follow-up, in the final model 27 of 487. Regression analyses with adjustment for confounders identified COPAVP and MRproANP as statistically robust biomarkers (p < 0.05 each) of all-cause mortality, while MRproADM and fibrinogen were not. The fourth quartile of MRproANP (97 pmol/L) was associated with a hazard ratio of 4.5 (95%CI: 1.6; 12.8), and the fourth quartile of COPAVP (9.2 pmol/L) with 3.0 (1.1; 8.0). The results for MRproANP were confirmed in the total cohort of grade 0-4 (n = 1470 finally) | ||
| 520 | |a CONCLUSION: In patients with recently diagnosed mild to moderate COPD, elevated values of COPVP and in particular MRproANP were robust, independent biomarkers for all-cause mortality risk after adjustment for multiple other factors. This suggests that these markers might be considered in the risk assessment of early COPD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COPAVP | |
| 650 | 4 | |a COPD | |
| 650 | 4 | |a COSYCONET | |
| 650 | 4 | |a MRproADM | |
| 650 | 4 | |a MRproANP | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Prospective multicenter cohort study | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a copeptins |2 NLM | |
| 650 | 7 | |a Fibrinogen |2 NLM | |
| 650 | 7 | |a 9001-32-5 |2 NLM | |
| 650 | 7 | |a Glycopeptides |2 NLM | |
| 650 | 7 | |a AVP protein, human |2 NLM | |
| 700 | 1 | |a Herr, C |e verfasserin |4 aut | |
| 700 | 1 | |a Teuteberg, S |e verfasserin |4 aut | |
| 700 | 1 | |a Alter, P |e verfasserin |4 aut | |
| 700 | 1 | |a Söhler, S |e verfasserin |4 aut | |
| 700 | 1 | |a Soriano, D |e verfasserin |4 aut | |
| 700 | 1 | |a Classen, J |e verfasserin |4 aut | |
| 700 | 1 | |a Adams, J |e verfasserin |4 aut | |
| 700 | 1 | |a Weinhold, V |e verfasserin |4 aut | |
| 700 | 1 | |a Watz, H |e verfasserin |4 aut | |
| 700 | 1 | |a Waschki, B |e verfasserin |4 aut | |
| 700 | 1 | |a Zeller, T |e verfasserin |4 aut | |
| 700 | 1 | |a Eichenlaub, M |e verfasserin |4 aut | |
| 700 | 1 | |a Trudzinski, F C |e verfasserin |4 aut | |
| 700 | 1 | |a Michels, J D |e verfasserin |4 aut | |
| 700 | 1 | |a Omlor, A |e verfasserin |4 aut | |
| 700 | 1 | |a Seiler, F |e verfasserin |4 aut | |
| 700 | 1 | |a Moneke, I |e verfasserin |4 aut | |
| 700 | 1 | |a Biertz, F |e verfasserin |4 aut | |
| 700 | 1 | |a Stolz, D |e verfasserin |4 aut | |
| 700 | 1 | |a Welte, T |e verfasserin |4 aut | |
| 700 | 1 | |a Kauczor, H U |e verfasserin |4 aut | |
| 700 | 1 | |a Kahnert, K |e verfasserin |4 aut | |
| 700 | 1 | |a Jörres, R A |e verfasserin |4 aut | |
| 700 | 1 | |a Vogelmeier, C F |e verfasserin |4 aut | |
| 700 | 1 | |a Bals, R |e verfasserin |4 aut | |
| 700 | 0 | |a German COSYCONET Cohort |e verfasserin |4 aut | |
| 700 | 1 | |a Andreas, Stefan |e investigator |4 oth | |
| 700 | 1 | |a Alter, Peter |e investigator |4 oth | |
| 700 | 1 | |a Bals, Robert |e investigator |4 oth | |
| 700 | 1 | |a Behr, Jürgen |e investigator |4 oth | |
| 700 | 1 | |a Kahnert, Kathrin |e investigator |4 oth | |
| 700 | 1 | |a Bahmer, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Bewig, Burkhard |e investigator |4 oth | |
| 700 | 1 | |a Ewert, Ralf |e investigator |4 oth | |
| 700 | 1 | |a Stubbe, Beate |e investigator |4 oth | |
| 700 | 1 | |a Ficker, Joachim H |e investigator |4 oth | |
| 700 | 1 | |a Grohé, Christian |e investigator |4 oth | |
| 700 | 1 | |a Held, Matthias |e investigator |4 oth | |
| 700 | 1 | |a Henke, Markus |e investigator |4 oth | |
| 700 | 1 | |a Herth, Felix |e investigator |4 oth | |
| 700 | 1 | |a Kirsten, Anne-Marie |e investigator |4 oth | |
| 700 | 1 | |a Watz, Henrik |e investigator |4 oth | |
| 700 | 1 | |a Koczulla, Rembert |e investigator |4 oth | |
| 700 | 1 | |a Kronsbein, Juliane |e investigator |4 oth | |
| 700 | 1 | |a Kropf-Sanchen, Cornelia |e investigator |4 oth | |
| 700 | 1 | |a Herzmann, Christian |e investigator |4 oth | |
| 700 | 1 | |a Pfeifer, Michael |e investigator |4 oth | |
| 700 | 1 | |a Randerath, Winfried J |e investigator |4 oth | |
| 700 | 1 | |a Seeger, Werner |e investigator |4 oth | |
| 700 | 1 | |a Studnicka, Michael |e investigator |4 oth | |
| 700 | 1 | |a Taube, Christian |e investigator |4 oth | |
| 700 | 1 | |a Timmermann, Hartmut |e investigator |4 oth | |
| 700 | 1 | |a Schmeck, Bernd |e investigator |4 oth | |
| 700 | 1 | |a Vogelmeier, Claus |e investigator |4 oth | |
| 700 | 1 | |a Welte, Tobias |e investigator |4 oth | |
| 700 | 1 | |a Wirtz, Hubert |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory research |d 2000 |g 25(2024), 1 vom: 24. Jan., Seite 56 |w (DE-627)NLM115627553 |x 1465-993X |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:1 |g day:24 |g month:01 |g pages:56 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12931-024-02690-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 1 |b 24 |c 01 |h 56 | ||